452 results on '"Pusceddu, Sara"'
Search Results
52. Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors
53. Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective
54. Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study
55. Lung carcinoid tumours: histology and Ki-67, the eternal rivalry.
56. Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study
57. Prognostic features of gastro‐entero‐pancreatic neuroendocrine neoplasms in primary and metastatic sites: Grade, mesenteric tumour deposits and emerging novelties
58. Target therapies plus somatostatin analogs in NETs: a network meta-analysis
59. Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer
60. Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan
61. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: An ITMO group study
62. From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours
63. Case Report: Exceptional Response to Avelumab After Failure of Electrochemotherapy in a Patient With Rapidly Progressive, PD-L1-Negative Merkel Cell Carcinoma
64. Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.
65. Myeloid and T-Cell Microenvironment Immune Features Identify Two Prognostic Sub-Groups in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms
66. Spartalizumab in metastatic, well/poorly differentiated neuroendocrine neoplasms
67. How to Recognize and Manage Psychosomatic Pain in the Pediatric Emergency Department
68. Well-differentiated neuroendocrine tumor of tailgut cyst. A rare entity with controversial medical opportunities
69. Sunitinib and everolimus in pancreatic neuroendocrine tumors
70. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms?
71. Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials
72. Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups
73. Health-related quality of life trajectory of treatment-naive patients with Merkel cell carcinoma receiving avelumab
74. One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches
75. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors
76. Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): a study protocol
77. Are Cyclin-Dependent Kinase 4/6 Inhibitors Without Future in Neuroendocrine Tumors?
78. First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade III well-differentiated neuroendocrine tumors (NET G3).
79. Combined use of albumin and neutrophil-to-lymphocyte ratio as new prognostic and predictive factor in patients with poorly differentiated neuroendocrine carcinomas.
80. Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis
81. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis
82. Statin Use Decreases the Incidence of Hepatocellular Carcinoma: An Updated Meta-Analysis
83. Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix
84. The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence
85. Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer
86. Biliary Stone Disease in Patients with Neuroendocrine Tumors Treated with Somatostatin Analogs: A Multicenter Study
87. Gastroenteropancreatic High-Grade Neuroendocrine Neoplasms: Histology and Molecular Analysis, Two Sides of the Same Coin
88. Nonconventional Doses of Somatostatin Analogs in Patients With Progressing Well-Differentiated Neuroendocrine Tumor
89. Impact of Metformin on Systemic Metabolism and Survival of Patients With Advanced Pancreatic Neuroendocrine Tumors
90. Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm
91. Somatostatin Analogs in Association with Peptide Receptor Radionucleotide Therapy in Advanced Well-Differentiated NETs
92. Microenvironment and tumor inflammatory features improve prognostic prediction in gastro‐entero‐pancreatic neuroendocrine neoplasms
93. Exploiting DNA repair alterations in metastatic pancreatic cancer (mPAC): Is MGMT methylation a new therapeutic target?
94. A novel subpopulation of circulating tumor cells in patients with cholangiocarcinoma.
95. Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis
96. Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs)
97. Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives
98. Ki-67 Index of 55% Distinguishes Two Groups of Bronchopulmonary Pure and Composite Large Cell Neuroendocrine Carcinomas with Distinct Prognosis.
99. Erratum: Real-world study of everolimus in advanced progressive neuroendocrine tumors (The Oncologist, (2014) 19, (966-974), 10.1634/theoncologist.2014-0037)
100. Le nuove Linee Guida sulla bronchiolite
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.